1. Home
  2. ERIE vs ILMN Comparison

ERIE vs ILMN Comparison

Compare ERIE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Erie Indemnity Company

ERIE

Erie Indemnity Company

HOLD

Current Price

$296.79

Market Cap

19.2B

Sector

Finance

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$128.82

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ERIE
ILMN
Founded
1925
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.2B
18.9B
IPO Year
1995
2000

Fundamental Metrics

Financial Performance
Metric
ERIE
ILMN
Price
$296.79
$128.82
Analyst Decision
Hold
Analyst Count
0
15
Target Price
N/A
$114.93
AVG Volume (30 Days)
131.9K
1.5M
Earning Date
10-30-2025
10-30-2025
Dividend Yield
1.84%
N/A
EPS Growth
15.90
N/A
EPS
12.39
4.46
Revenue
$4,040,325,000.00
$4,288,000,000.00
Revenue This Year
$9.98
N/A
Revenue Next Year
$5.75
$2.08
P/E Ratio
$23.93
$28.91
Revenue Growth
9.53
N/A
52 Week Low
$276.91
$68.70
52 Week High
$456.93
$153.06

Technical Indicators

Market Signals
Indicator
ERIE
ILMN
Relative Strength Index (RSI) 49.40 66.70
Support Level $292.47 $124.27
Resistance Level $301.14 $129.72
Average True Range (ATR) 5.59 3.90
MACD 2.03 -0.41
Stochastic Oscillator 71.66 77.82

Price Performance

Historical Comparison
ERIE
ILMN

About ERIE Erie Indemnity Company

Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: